Making progress against rare cancers: A case study on neuroendocrine tumors

In April 2023, the National Cancer Institute offered a roadmap for cancer research to achieve Cancer Moonshot goals. To reach these goals requires making progress for all cancers, not just those that are most common. Achieving progress against rare cancers, as well as common cancers, requires involv...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2024-05, Vol.130 (9), p.1568-1574
Hauptverfasser: O’Rorke, Michael, Chrischilles, Elizabeth, Chamberlain, Alanna M., Chrischilles, Elizabeth A., Cowell, Lindsay G., Dillon, Joseph S., Early, Carol, Else, Tobias, Gamblin, T. Clark, Geller, David, Gellerman, Elyse, Gryzlak, Brian, Halfdanarson, Thorvardur R., Hamilton, Harley C., He, Fiona C., Hourcade, Juan Pablo, Indrees, Kamran, Kazmi, Syed M., Lancaster, William, Lewis‐Hughes, Amoni, Liu, Mei, Mailman, Josh A., McDowell, Bradley, Ramirez, Robert A., Ramnaraign, Brian H., Sanoff, Hanna K., Soares, Heloisa P., Sukrithan, Vineeth, Taylor, Bradley W., Tepper, Mia S., Wahmann, Maryann, Zamba, Gideon K. D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In April 2023, the National Cancer Institute offered a roadmap for cancer research to achieve Cancer Moonshot goals. To reach these goals requires making progress for all cancers, not just those that are most common. Achieving progress against rare cancers, as well as common cancers, requires involvement of large clinical research networks. In 2020, the Patient‐Centered Outcomes Research Institute (PCORI) launched an initiative on Conducting Rare Disease Research using PCORnet, the National Patient‐Centered Clinical Research Network. The purpose of this commentary is to introduce the broader community of cancer researchers to the PCORnet NET‐PRO study (comparing the effects of different treatment approaches for neuroendocrine tumors on patient‐reported outcomes) thereby demonstrating how researchers can use the PCORnet infrastructure to conduct large‐scale patient‐centered studies of rare cancers. Achieving progress against rare cancers requires involvement of large clinical research networks. This commentary showcases the NET‐PRO study (comparing the effects of different treatment approaches for neuroendocrine tumors on patient‐reported outcomes) to demonstrate how cancer researchers can conduct large‐scale patient‐centered studies of rare cancers using PCORnet.
ISSN:0008-543X
1097-0142
1097-0142
DOI:10.1002/cncr.35184